521 related articles for article (PubMed ID: 20956629)
1. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Dimopoulos MA; Terpos E; Chanan-Khan A; Leung N; Ludwig H; Jagannath S; Niesvizky R; Giralt S; Fermand JP; Bladé J; Comenzo RL; Sezer O; Palumbo A; Harousseau JL; Richardson PG; Barlogie B; Anderson KC; Sonneveld P; Tosi P; Cavo M; Rajkumar SV; Durie BG; San Miguel J
J Clin Oncol; 2010 Nov; 28(33):4976-84. PubMed ID: 20956629
[TBL] [Abstract][Full Text] [Related]
2. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
3. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and treatment of renal failure in multiple myeloma.
Dimopoulos MA; Kastritis E; Rosinol L; Bladé J; Ludwig H
Leukemia; 2008 Aug; 22(8):1485-93. PubMed ID: 18528426
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
7. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Renal Impairment of Multiple Myeloma Collaborative Study Group
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
9. Renal insufficiency and failure.
Dimopoulos MA; Terpos E
Hematology Am Soc Hematol Educ Program; 2010; 2010():431-6. PubMed ID: 21239831
[TBL] [Abstract][Full Text] [Related]
10. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
11. Management of myeloma-associated renal dysfunction in the era of novel therapies.
Gaballa MR; Laubach JP; Schlossman RL; Redman K; Noonan K; Mitsiades CS; Ghobrial IM; Munshi N; Anderson KC; Richardson PG
Expert Rev Hematol; 2012 Feb; 5(1):51-66; quiz 67-8. PubMed ID: 22272706
[TBL] [Abstract][Full Text] [Related]
12. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
13. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
17. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
[TBL] [Abstract][Full Text] [Related]
19. Current treatments for renal failure due to multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Scheid C; Sonneveld P; Schmidt-Wolf IG; van der Holt B; el Jarari L; Bertsch U; Salwender H; Zweegman S; Blau IW; Vellenga E; Weisel K; Pfreundschuh M; Jie KS; Neben K; van de Velde H; Duehrsen U; Schaafsma MR; Lindemann W; Kersten MJ; Peter N; Hänel M; Croockewit S; Martin H; Wittebol S; Bos GM; van Marwijk-Kooy M; Wijermans P; Goldschmidt H; Lokhorst HM
Haematologica; 2014 Jan; 99(1):148-54. PubMed ID: 23996482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
